Medigrowth named Gold Sponsor of National Pain Week 2026

Medigrowth Australia will back Chronic Pain Australia’s National Pain Week from 26-31 July 2026 as Gold Sponsor, with a campaign focused on chronic pain education and medicinal cannabis awareness. The partnership comes as survey data show growing use and interest in medicinal cannabis among Australians managing chronic pain.

Why it matters: - National Pain Week reaches Australians living with chronic pain at a time when survey data point to rising interest in medicinal cannabis as a treatment option. - The partnership aims to reduce stigma, improve access to reliable information and support more informed care conversations with qualified health professionals. - Chronic Pain Australia says the sponsorship helps push for chronic pain to be recognised as a National Health Priority Area.

What happened: - Medigrowth Australia was announced as Gold Sponsor of National Pain Week 2026. - The campaign runs from 26 to 31 July 2026. - Chronic Pain Australia is the organiser of National Pain Week and the National Pain Survey. - Medigrowth will also be Gold Sponsor of the 2026 National Pain Report.

The details: - Medigrowth produced a five-part video series for the campaign covering common questions about medicinal cannabis, including whether it works, what it feels like and whether other people will know someone has tried it. - The series includes titles such as “What’s the Deal with Medicinal Cannabis?”, “What Does Medicinal Cannabis Feel Like?”, “Will People Know I’ve Tried Medicinal Cannabis?”, “Will Medicinal Cannabis Work for Me?” and “Will Medicinal Cannabis Get Me High?” - The partnership also includes a longer interview, “Pain Lives in Women’s Health,” featuring Medigrowth’s Melanie Wentzel and Chronic Pain Australia General Manager Kellie Jade Ellis. - The interview covers healthcare leadership and Ellis’s own endometriosis journey. - Chronic Pain Australia says the National Pain Survey is the longest-running survey documenting the experiences of Australians living with chronic pain. - The past three National Pain Reports show medicinal cannabis playing a growing role in chronic pain management. - In 2025, 31% of respondents said they had accessed medicinal cannabis for pain management, up from 28% in 2024. - Another 27.5% said they would like to or intend to try medicinal cannabis. - That means more than half of respondents either use medicinal cannabis or are interested in it as a treatment option. - The same reports say cost and driving restrictions have each eased slightly year over year. - Medigrowth describes itself as an Australian biotechnology, digital health and clinical research organisation focused on cannabinoid therapeutics and evidence-based healthcare. - Medigrowth says its work includes clinical research, cannabinoid therapeutics for the Australian market and patient care through its digital health platform, Azure Health. - Medigrowth says its research includes a randomised, double-blind, placebo-controlled clinical trial with Deakin University and Swinburne University on CBD in children and families living with autism. - Medigrowth says the EMPOWER Project is a prospective, HREC-approved real-world evidence study following up to 5,000 patients over four years. - Chronic Pain Australia says it is a non-profit, non-government organisation and the national voice for the 3.6 million Australians living with chronic pain. - Chronic Pain Australia says it was founded in 2001 and runs PainLink support services and a national network of peer-led Pain Support Groups. - Medigrowth and Chronic Pain Australia both frame the partnership as a person-centred effort to support people living with chronic and complex pain conditions.

Between the lines: - The sponsorship gives Medigrowth a prominent role in a national awareness campaign at a moment when medicinal cannabis is becoming more visible in chronic pain care. - The campaign messaging suggests both organisations see education and stigma reduction as the main barriers, not just access to products or services. - The focus on women’s health and endometriosis also signals an effort to connect chronic pain advocacy with conditions that are often underdiagnosed or undertreated.

What's next: - National Pain Week will run 26-31 July 2026. - Medigrowth will be featured through the video series and the National Pain Report sponsorship during the campaign period. - Chronic Pain Australia will continue using National Pain Week, the National Pain Survey and related support services to amplify patient experiences and advocacy. - More information is available at Medigrowth Australia and Chronic Pain Australia.

The bottom line: - Medigrowth is using National Pain Week 2026 to put medicinal cannabis and chronic pain education in front of a national audience, while Chronic Pain Australia gains a major sponsor for its biggest awareness push of the year.